L-glutamine powder is a fermentation-derived amino acid used in sports nutrition powders, protein blends, stick packs, capsules, tablets and other functional nutrition products. Bulk buyers should evaluate more than assay. Identity, particle size, moisture, density, contaminants, documentation and dosage-form performance can all affect material approval and commercial production.
Essencefield supplies L-glutamine powder within its broader nutrition ingredient portfolio. The final grade, specification, packaging, minimum order quantity and lead time are confirmed according to the approved source and individual project.
Commercial and Technical Supply Snapshot
| Item | Supply reference |
|---|---|
| Product name | L-Glutamine Powder |
| CAS number | 56-85-9 |
| Molecular formula | C5H10N2O3 |
| Ingredient category | Free-form amino acid |
| Typical source | Fermentation-derived |
| Typical assay | ≥99.0% on a dry basis when specified |
| Appearance | White to off-white crystalline powder |
| Available grade | Food, supplement or project-specific grade |
| Particle size | Project-specific PSD |
| Bulk density | Lot-dependent; available for filling assessment |
| Carrier | Normally supplied without a carrier |
| Standard packing | Typically 20–25 kg carton or fiber drum |
| Shelf life | Typically 24 months unopened under recommended storage |
| Sample availability | Available after project review |
| MOQ | Project-specific |
| Lead time | Confirmed with quotation |
| Documents | COA, specification or TDS, SDS and applicable declarations |
These values are commercial references, not universal release limits. Buyers should request the current specification and a representative batch Certificate of Analysis before approving the source.
Request the current specification and representative COA before sampling or purchasing.
Identity, Source and Grade
L-glutamine is the optically active L-form of glutamine. The PubChem record for L-glutamine, maintained by the U.S. National Library of Medicine, identifies CAS 56-85-9 and the molecular formula C5H10N2O3.
The FDA’s Substances Added to Food database also lists L-glutamine and identifies technical effects that include nutrient supplementation and selected flavor-related uses. These references help establish chemical identity and food-use context but do not replace destination-market or finished-product review.
Commercial L-glutamine is commonly made through microbial fermentation followed by purification and crystallization. Where relevant, buyers should request confirmation of:
- Manufacturing source and location
- Fermentation origin
- Non-animal status
- GMO documentation
- Allergen status
- Country of origin
- Batch traceability
- Change-notification procedures
Fermentation origin does not replace batch testing. The commercial material must still comply with the approved identity, purity, physical-property and contaminant limits.
Interpreting grade terminology
| Grade term | Buyer interpretation |
|---|---|
| Food or supplement grade | Intended-use description; approve the actual specification and market requirements |
| USP or FCC | Confirm the applicable monograph, edition, methods and batch compliance |
| Project-specific grade | Limits are agreed according to the formula and manufacturing process |
| Pharmaceutical grade | Do not rely on the phrase without a named pharmacopoeia, manufacturing scope and intended drug use |
The correct material is the source that consistently meets the approved specification and works in the intended dosage form—not necessarily the one with the highest headline purity.
How to Review an L-Glutamine COA
A Certificate of Analysis should connect a specific production lot to the signed purchasing specification. It should identify the material, batch, analytical methods, acceptance criteria and actual results.
| COA parameter | Buyer review | Manufacturing relevance | Warning sign |
|---|---|---|---|
| Identification | Method, reference standard and result | Confirms the correct ingredient | Identity based only on appearance |
| Assay | Method, range and dry/as-is basis | Formula and label calculations | Reporting basis is not stated |
| Optical rotation | Solvent, concentration and temperature | Supports L-form verification | Result lacks test conditions |
| Related substances | Method and impurity profile | Heat- or stability-sensitive products | No impurity strategy |
| Loss on drying | Method and numerical limit | Flow, caking and storage | Result approaches the upper limit |
| Particle size | Sieve limits or full PSD | Wetting, filling and segregation | Only “fine powder” is stated |
| Bulk density | Method and representative range | Capsule capacity and pack volume | Sample and batch differ significantly |
| Heavy metals | Individual element results | Exposure and market compliance | Only a general “pass” result |
| Microbiology | Numerical limits and pathogen panel | Hygienic raw-material release | Organisms or methods are incomplete |
| Document consistency | Product, lot and specification match | Traceability and batch release | Label and COA identify different lots |
Essencefield’s product and quality framework may include HPLC or equivalent identification, assay, particle-size testing, bulk-density review, loss on drying, microbiology, elemental impurities and related-substance testing under an agreed specification.
For assay, buyers should confirm whether the result is reported on a dry or as-is basis. These calculations are not interchangeable when the material contains measurable moisture.
Identity methods should match the signed specification. HPLC retention comparison, FTIR and optical rotation can serve different purposes and should not be treated as interchangeable tests.
Microbiological and elemental impurity limits should reflect:
- Destination-market requirements
- Intended daily intake
- Other ingredients in the formula
- Dosage form
- Target consumer
- Finished-product limits
Element-specific results for lead, arsenic, cadmium and mercury are generally more useful than a combined heavy-metals result.
Particle Size, Bulk Density and Moisture
Chemical assay alone cannot predict how a powder will behave during blending, conveying, filling or consumer preparation.
Particle-size distribution
Particle size can affect:
- Powder flow
- Dust generation
- Wetting and dispersion
- Blend segregation
- Mouthfeel
- Sachet and capsule filling
- Tablet compression
A finer material may wet more quickly but can retain air, produce more dust and flow less consistently. A controlled or slightly coarser grade may improve filling but require more mixing time.
The purchasing specification should therefore define a measurable mesh range or particle-size distribution based on application testing.
Bulk density
Bulk density affects:
- Capsule fill capacity
- Number of capsules per serving
- Jar or pouch volume
- Hopper behavior
- Blend uniformity
Two sources with comparable assay results may require different capsule sizes or package volumes because their densities differ.
Capsule, sachet and tablet projects should use representative commercial material for density and flow testing. Laboratory samples may not reproduce the physical behavior of a production lot.
Moisture control
Loss on drying measures moisture removed under defined test conditions. Water activity indicates how much water is available within the powder system. These measurements are related but not equivalent.
Excess moisture can increase:
- Caking
- Poor hopper discharge
- Fill-weight variation
- Storage instability
- Packaging requirements
Buyers should review moisture results together with the liner, outer package, storage conditions and transport humidity. Cool, dry storage and prompt resealing after opening help protect the material.
Dosage-Form Suitability
| Dosage form | Main advantage | Main risk | Recommended evaluation |
|---|---|---|---|
| Standalone powder | Accommodates gram-level servings | Caking, taste and scoop variation | Full-serving dispersion and packaging trial |
| Stick pack or sachet | Unit-dose convenience | Fill variation and humidity | Pilot filling and seal-integrity testing |
| Amino acid blend | Supports multi-ingredient formulas | Density-driven segregation | Multi-point blend-uniformity study |
| Capsule | Familiar dosage format | Excessive capsule count | Density, flow and fill-weight assessment |
| Tablet | Compact presentation | Compression or sticking problems | Pilot compression and disintegration |
| Protein blend | Relevant to sports nutrition | Clumping and flavor interaction | Complete-formula mixing trial |
| Gummy | Consumer-friendly format | Heat and water exposure | Assay and stability study |
| Ready-to-drink | Immediate convenience | Solution degradation | Full process and shelf-life validation |
High-dose powder products
Powder formats are generally the most practical option when a formula contains several grams of L-glutamine per serving.
Bench testing should use the intended serving size and complete formulation. Solubility in plain water does not predict wetting, taste or sediment in a product containing proteins, acids, minerals, sweeteners or flavors.
Essencefield’s powder supplement manufacturing support includes formula review, sample preparation, powder-behavior assessment, filling compatibility and packaging coordination.
Capsules and tablets
Capsule feasibility depends on bulk density, flowability, shell size and active loading. A low-density material may require more capsules than the brand considers commercially acceptable.
Tablet projects also require testing for:
- Compressibility
- Hardness
- Friability
- Capping
- Sticking
- Disintegration
A compliant raw-material COA does not demonstrate that the ingredient will run successfully on commercial filling or compression equipment.
Gummies and liquid products
Heat and water increase stability risk. A ready-to-mix powder may therefore be more practical than a long-shelf-life liquid.
Published research on the stability of L-glutamine in solution found that degradation varies with solution and storage conditions and can produce ammonia. Gummies, liquid products and heat-exposed formulas should be supported by finished-product stability studies.
Evidence and Claim Boundaries
| Positioning area | Evidence interpretation | Commercial limitation |
|---|---|---|
| Intestinal barrier | Mechanistic and selected clinical evidence exists | Do not imply treatment of gastrointestinal disease |
| Sports nutrition | Glutamine participates in amino acid and nitrogen metabolism | Do not promise muscle growth or improved performance without substantiation |
| Immune function | Glutamine is involved in immune-cell metabolism | Avoid infection-prevention and disease claims |
| Prescription use | Approved L-glutamine drugs have defined indications | Drug approval does not transfer to supplement ingredients |
A 2024 systematic review and meta-analysis reported an overall effect on intestinal permeability across the included trials, but the results depended on population, dose and study design.
Evidence from defined clinical groups should not be converted into universal supplement claims. FDA guidance on structure/function claims distinguishes statements about normal physiological roles from claims that a product diagnoses, treats, cures or prevents disease.
Prescription L-glutamine products operate under a separate drug framework. The DailyMed listing for Endari does not establish treatment claims for conventional food- or supplement-grade raw material.
Supplier Qualification and Batch Approval
A controlled approval process should connect the manufacturer, specification, documents, sample and commercial batch.
1. Confirm the manufacturer and source
Identify:
- Legal manufacturer
- Distributor or exporter
- Production location
- Country of origin
- Responsible quality organization
- Change-notification process
The supply chain should support traceability, deviation review, complaint handling and recall investigation.
2. Approve the specification
Define the required:
- Identity methods
- Assay and reporting basis
- Particle-size distribution
- Moisture limit
- Bulk density where relevant
- Microbiological limits
- Elemental impurity limits
- Packaging
- Storage
- Shelf life or retest period
3. Cross-check batch documents
Confirm that the following information matches across the specification, COA, label and declarations:
- Product name
- CAS number
- Product code
- Batch number
- Manufacturing source
- Specification version
- Test methods
- Manufacture and retest dates
- Certification holder and scope
Essencefield’s raw-material quality process connects supplier qualification, specification approval, COA review, incoming inspection, release decisions and batch traceability.
4. Test a representative sample
The sample should represent the proposed commercial source and grade.
Evaluation may include:
- Identity verification
- Dispersion testing
- Sensory review
- Blend-uniformity studies
- Capsule or tablet trials
- Pilot production
- Preliminary stability observations
Essencefield’s ingredient sourcing service supports specification matching, document review, sample coordination, testing and bulk supply planning.
5. Review multiple batches
Where data are available, compare several recent COAs for:
- Assay
- Moisture
- Particle size
- Density
- Microbiology
- Elemental impurities
A multi-batch review provides a better indication of source consistency than a single ideal COA.
6. Establish change control
Require notification for significant changes involving:
- Manufacturing site
- Production route
- Raw-material source
- Specification
- Analytical method
- Particle-size process
- Packaging
- Shelf life
- Regulatory status
A batch should be placed on hold when its identity is unclear, its methods differ from the approved specification or its documents cannot be linked to the approved source.
Documentation, Price and RFQ
Standard document package
| Document | Procurement purpose |
|---|---|
| Batch COA | Confirms actual results against the specification |
| Specification or TDS | Defines identity, limits and technical properties |
| SDS | Supports handling, storage and transport review |
| Allergen statement | Supports formula and label assessment |
| GMO statement | Supports sourcing requirements |
| Vegan or non-animal statement | Confirms origin suitability where required |
| Irradiation statement | Supports market and customer review |
| Country-of-origin statement | Supports imports and traceability |
| Third-party report | Provides independent confirmation when requested |
Essencefield’s testing and certification support can coordinate technical documents and third-party testing where required. Certificate applicability should be confirmed against the product, manufacturing facility and destination market.
Factors affecting bulk price
Bulk quotations can vary according to:
- Grade and assay
- Analytical scope
- Particle-size requirements
- Contaminant limits
- Documents and declarations
- Packaging
- Order volume
- Shipping route
- Incoterm
- Lead time
Compare quotations using the same specification, test scope, packaging and delivery term.
Information required for an RFQ
Provide:
- Product name and required grade
- Intended dosage form
- Target serving or inclusion level
- Required assay and identity methods
- Particle-size preference
- Moisture and contaminant limits
- Trial quantity
- Estimated annual demand
- Destination country
- Required documents
- Packaging preference
- Target delivery date
- Third-party testing requirements
A complete RFQ allows the offered material, documentation and price to be matched to the actual manufacturing project.
Essencefield L-Glutamine Supply Support
Essencefield supports specification and source matching, sample and COA review, dosage-form assessment, testing coordination and bulk supply planning.
Project-specific particle size, packaging, MOQ, lead time and document requirements are confirmed after technical review. The approved source can then be connected to incoming inspection, commercial batch release and repeat-order traceability.
Contact Essencefield to request the current L-glutamine specification, representative COA, sample, packaging details and quotation.

















